Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pegcetacoplan versus placebo in cold agglutinin disease
jRCT2031220441Phase 3Suspended
- Sponsor
- Sobi
- Start
- Mar 2023
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in cold agglutinin disease (CAD) comparing Pegcetacoplan with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Mar 2023; status: suspended.
02
Drugs
pegcetacoplan
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on jRCT2031220441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220441.